The Efficacy of Combination of Avatrombopag and rhIL-11 in Adult Patients of Acute Myeloid Leukemia with Cancer Treatment-Induced Thrombocytopenia.
10.19746/j.cnki.issn.1009-2137.2025.03.033
- Author:
Min-Na LUO
1
;
Hai-Tao ZHANG
1
;
Si-Jie ZHAO
1
;
Jing LI
1
;
Wen-Juan WANG
1
;
Peng-Cheng HE
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China.
- Publication Type:Journal Article
- Keywords:
avatrombopag;
acute myeloid leukemia;
cancer treatment-induced thrombocytopenia
- MeSH:
Humans;
Leukemia, Myeloid, Acute/drug therapy*;
Thrombocytopenia/chemically induced*;
Interleukin-11/therapeutic use*;
Retrospective Studies;
Adult;
Thiophenes/therapeutic use*;
Platelet Count;
Female;
Male;
Middle Aged;
Thiazoles
- From:
Journal of Experimental Hematology
2025;33(3):848-852
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the safety and efficacy of avatrombopag（AVA） combined with rhIL-11 in treating thrombocytopenia induced by chemotherapy in acute myeloid leukemia.
METHODS:The clinical information of 8 patients in the real world who received avatrombopag combined with rhIL-11 in cancer treatment-induced thrombocytopenia(CTIT) after AML chemotherapy were retrospectively analyzed, and at the same time, 8 patients who received rhIL-11 only in CTIT after AML chemotherapy served as the control group, A preliminary observation was to summarize and compare the therapeutic efficacy and adverse effects between the two groups.
RESULTS:D3 and D7 platelet counts were not significantly different between the observation group and the control group after treatment. The platelet counts in the observation group was significantly higher than those of the control group on the 10th day after treatment (P < 0.01). The adverse reactions, such as weakness, abdominal pain, fatigue, nausea and edema after treatment were mild in the observation group and the control group. Except for one patient in the observation group who had a history of cerebral infarction before the onset of the disease and was routinely taking antiplatelet drugs, no thrombosis events occurred in the patients in the observation and control groups during the period of administration of the drug, and the total incidence rate of adverse reactions was not significantly different between the two groups.
CONCLUSION:The combination of AVA and rhIL-11 can enhance platelet recovery in CTIT of AML patients after chemotherapy. Compared with the rhIL-11 alone group, the platelet recovery time in AVA+rhIL-11 group was significantly shorter, the platelet count on the 10th day after drug administration was significantly higher. No statistically significant difference in the total incidence rate of adverse reactions was observed between rhIL-11 alone group and AVA+rhIL-11 group.
